Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905979 · ClinicalTrials.gov registry record · Phase 2
Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
A Phase 2 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04905979 is a Phase 2 study that has completed, run by Apnimed. The registered enrollment target is 21 participants.
The verdict
NCT04905979, a Phase 2 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a randomized, double blind, 2-period, non placebo-controlled crossover study in patients with moderate to severe OSA and controlled hypertension, comparing atomoxetine with AD113
Interventions
- DRUG Atomoxetine
- DRUG AD113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-07-31 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04905979
The ClinicalTrials.gov registry entry for NCT04905979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atomoxetine is the first listed.
NCT04905979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04905979 about?
NCT04905979 is a clinical study titled "Trial of AD113 and Atomoxetine in OSA Patients With Hypertension". This is a randomized, double blind, 2-period, non placebo-controlled crossover study in patients with moderate to severe OSA and controlled hypertension, comparing atomoxetine with AD113
What is the current status of trial NCT04905979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2021-07-31. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04905979?
The interventions under investigation include: Atomoxetine (DRUG), AD113 (DRUG).
Who is sponsoring clinical trial NCT04905979?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.